Background: Pectoral plane blocks (PECs) are increasingly used in analgesia for patients undergoing breast surgery, and were recently found to be at least equivalent to single-shot paravertebral anaesthesia. However, there are no data comparing PECs with the popular practice of continuous local anaesthetic wound infusion (LA infusion) analgesia for breast surgery. Therefore, we compared the efficacy and safety of PECs blocks with LA infusion, or a combination of both in patients undergoing non-ambulatory breast-cancer surgery. Methods: This single-centre, prospective, randomised, double-blind trial analysed 45 women to receive either PECs blocks [levobupivacaine 0.25%, 10 ml PECs I and levobupivacaine 0.25%, 20 ml PECs II (PECs group); LA infusion catheter (levobupivacaine 0.1% at 10 ml h À1 for 24 h (LA infusion group); or both (PECs and LA infusion)]. The primary outcome
Editor's key points
Breast-cancer surgery requires careful control of postoperative pain for immediate and long-term benefit. Regional analgesia, with reduced opioid requirements, may confer some benefits in this patient group. This double-blind randomised controlled trial evaluates two different regional anaesthetic techniques alone and in combination. Single-shot pectoral plane blocks, together with local anaesthetic wound infusion, provided optimal analgesia. This promising result would support the need for further, larger studies in this area.
Breast surgery is associated with significant postoperative pain in a vulnerable patient group. 1 A number of analgesic strategies exist as part of a multimodal framework. Opioids are commonly used, although issues with their use are widely documented. Regional anaesthetic techniques are prevalent in clinical practice. Thoracic paravertebral blocks (TPVBs), given as single shot, and continuous local anaesthetic wound infusion (LA infusion) catheters are more effective than placebo, and reduce postoperative pain and opioid consumption. Pectoral plane (PECs) blocks are recently described. PECs I is deposition of local anaesthetic between pectoralis major and minor muscles at the third rib level. 9 PECs II is an extension of PECs I, with placement of additional local anaesthetic between pectoralis minor and serratus anterior muscles. 10 Single-shot PECs blocks are superior to placebo 11, 12 and recently also at least equivalent to single-shot TPVB in a small, single (investigator)-blind trial, 13, 14 although both PECs and TPVB gave good early (0e12 h) analgesia. LA infusion analgesia provides better late (12e24 h) analgesia than the single-shot TPVB. 8 Whilst single-shot PECs blocks have been rapidly adopted into clinical practice, it is not yet known if they provide adequate late analgesia when compared with available alternatives, or if a combined PECs and LA infusion approach would lead to improved results. There is a dearth of methodologically high-quality clinical trials evaluating either of these techniques in practice. Therefore, we aimed to compare the analgesic efficacy of single-shot PECs block vs LA infusion vs a combination of both PECs block and LA infusion, in women undergoing nonambulatory breast surgery.
Methods
The Non-ambulatory breast-cancer surgery encompassed wide local excision (WLE) with lymph-node resection, simple mastectomy, and mastectomy with sentinel lymph-node resection. Those undergoing latissimus dorsi or deep inferior epigastric perforator flap reconstruction were excluded.
Patients with chronic-pain syndromes, local anaesthetic allergy, contraindication to simple analgesics, local infection over the proposed block site, coagulopathy, or comorbid conditions precluding the provision of informed consent were excluded. All patients were day-of-surgery admission and attended a preoperative anaesthetic assessment clinic.
The patients were allocated into three groups using computer-generated randomisation, with the study number and group allocation concealed in sealed envelopes. Blocked randomisation in groups of nine was applied, giving similar numbers in each group as the study progressed. Groups were named 'PECs', 'local anaesthetic infusion (LA infusion)', and 'both (PECs and LA infusion)', which were evenly distributed to opaque envelopes numbered 1e45 in accordance with randomisation. The randomisation key was held by an independent party and was not used to reveal participant group allocations until data analysis commenced. PECs patients received the blocks and a sham wound-infiltration catheter. LA infusion patients received a continuous LA infusion catheter. PECs and LA infusion patients received a combination of techniques, without the initial local anaesthetic bolus via the wound infusion catheter. PECs blocks were performed whilst patients were under general anaesthesia, before the commencement of surgery. The operative surgeon sited wound infusion catheters during skin closure at the end of surgery.
The patients were induced with fentanyl 1e2 mg kg À1 , followed by propofol titrated to the absence of verbal response. Anaesthesia was maintained using an oxygen, air, and sevoflurane combination. Airway management and lungventilation strategies were at the discretion of the supervising anaesthetist. The patients received a standard intraoperative analgesic regimen of paracetamol 1 g and dexketoprofen 50 mg i.v., with rescue morphine as deemed necessary. Combination anti-emetics, including ondansetron 0.1e0. 15 15 An electronic anaesthetic record was used to document physiological parameters. Perioperative events, such as induction of anaesthesia, initial skin incision, and end of surgery, were annotated on the record. PECs blocks were performed on the side of surgery, using the ultrasound-guided technique described by Blanco 9 and
Blanco and colleagues. 10 The patient was placed in the supine, head-up, position with the arm abducted. The skin was prepared with chlorhexidine gluconate 2%/isopropyl alcohol 70% (ChloraPrep; Becton Dickinson, New Jersey, NJ, USA). They were performed with a 22-gauge echogenic needle (Ultraplex 360 cannula; B. Braun, Hessen, Germany; 50e80 mm), using the same ultrasound machine (SonoSite Edge; SonoSite, Inc., Bothell, WA, USA) and transducer (SonoSite HFL 50x; SonoSite, Inc.). The ultrasound probe was placed inferolaterally at the mid-clavicular level. The axillary artery and vein were identified, and the probe moved laterally until pectoralis major, pectoralis minor, and serratus anterior muscles were located at the level of the third rib. A needle in-plane approach was taken until the needle tip was positioned in the plane between pectoralis major and minor muscles, and levobupivacaine 0.25%, 10 ml was injected. The needle was advanced until it occupied the space between pectoralis minor and serratus anterior muscles, and a further levobupivacaine 0.25%, 20 ml was injected. Because of time pressure to proceed with surgery, the patients immediately received general anaesthesia, without documentation of the dermatomal sensory distribution of the block. Although the LA infusion group patients did not receive a sham PECs block, they remained nonetheless masked to their group allocation, because PECs blocks were performed under general anaesthesia. All patients had a wound infusion catheter sited and attached to an elastomeric pump (ON-Q PainBuster; B. Braun), which was placed by the operating surgeon. The catheter was sited at the level of the chest wall after surgery, and directed to pass through all muscle tissue and residual breast tissue layers during skin closure. For blinding purposes, patients in the PECs group received a sham woundinfiltration catheter system. LA infusion and PECs and LA infusion consisted of levobupivacaine 0.1% at 10 ml h À1 for 24 h after operation, whilst PECs patients received sodium chloride 0.9% at the same rate. LA infusion patients were administered an initial bolus of levobupivacaine 0.25%, 20 ml at the end of surgery. Those who performed the procedures, or were involved in the perioperative management, were not involved in postoperative pain assessment or data collection. Study interventions as described occurred whilst patients were under general anaesthesia. The patients were monitored for 24 h after surgery, initially in the post-anaesthesia care unit (PACU), and then at ward level once the PACU discharge criteria were met. Oxycodone 1e2 mg i.v. as required was prescribed for rescue analgesia in the PACU until the verbal rating scale (VRS) pain score was 2, in accordance with our standard protocol. A standard analgesic protocol of paracetamol 1 g orally (PO)/i.v. 6 hourly regular, ibuprofen 400 mg PO 8 hourly regular, and oxycodone immediate release 5e10 mg 1 hourly as required for rescue analgesia was prescribed for all patients. Ondansetron 4e8 mg i.v. 8 hourly as required was prescribed in the event of PONV.
The primary outcome measure of the study was area under the curve (AUC) of the VRS of pain moving vs time, where VRS pain was measured at 1, 4e6, 10e14, and 20e24 h after operation. The VRS is regarded as a valid, reliable, and easily understood pain-assessment tool in common clinical practice. 16 The assessment of pain in each patient was recorded after a brief explanation of the VRS to each patient. The patients were asked to rate their current pain on a Likert scale of 0e10, with 0 being equal to no pain at all and 10 being the worse pain that the patients have experienced. The number selected by each patient at that time interval was recorded. At each assessment, the patients were invited to report their pain VRS pain at rest and whilst moving. Pain whilst moving was defined as pain experienced whilst sitting forward from a recumbent position. Secondary outcome measures were total opioid consumption over a 24 h period and presence of adverse events. An investigator masked to group allocations recorded vital signs, pain scores, anti-emetic administration, and opioid use after operation. Adverse events, such as sedation, respiratory depression, hypotension, pruritus, and PONV, were also recorded. Respiratory depression was defined as bradypnoea (ventilatory frequency 8 bpm). Pruritus and sedation were evaluated because they are known adverse effects associated with opioids, which were the rescue medication available in this study.
Statistical analysis
Data were analysed by GraphPad Prism version 6 (GraphPad, Salt Lake City, UT, USA). The primary endpoint was area under the VRS, for pain on moving, vs time curve (AUC). We powered the study to detect a 25% difference in AUC from an internal pilot study, which indicated mean AUC of 60 cm h À1 [standard deviation (SD) 5e10] amongst patients receiving PECs or LA infusion in our clinical service, to 45 cm h À1 . We had observed the SD of the AUC to be in the order of 15 cm h À1 . Assuming a Type I error of 0.05 and a Type II error of 0.1, then n¼11 patients would be required for each group to detect this difference with 90% power. We obtained IRB permission for n¼15 each group to allow for protocol violations or patient dropout. Data were collected at 1, 4e6, 12e14, and 20e24 h after operation. They were tested for distribution initially using the KolmogoroveSmirnov test. For each patient, their AUC both moving and at rest was calculated by plotting their pain VRS vs time using GraphPad Prism version 6. The mean AUC according to the three study groups was then calculated and inspected for distribution, as described previously, and all AUC data were found to be normally distributed. Therefore, AUC data are expressed as mean (SD) and were compared using analysis of variance with post hoc Bonferroni correction for multiple two-group comparisons. Non-normally distributed data were compared using the KruskaleWallis test for repeated measurements. Categorical data (e.g. the incidence of potential adverse effects) were compared using Fischer's exact test where appropriate. P<0.05 was deemed statistically significant.
Results
The Consolidated Standards of Reporting Trials flow diagram for this trial is shown in Figure 1 . Whilst n¼186 patients were screened as potentially suitable, n¼45 met inclusion criteria and were randomised. All randomised patients were followed up according to the protocol. Baseline patient-characteristic data collected, including age, gender, weight, height, ASA status, and type of surgery, were comparable for all three patient groups. Most patients in each group underwent mastectomy with sentinel lymph-node biopsy (SLNB). The remaining patients in each group underwent WLE ± SLNB. Within the PECs group, 66% had a mastectomy (n¼10), with 33% having a WLE (n¼5). Within the LA infusion group, 73% underwent mastectomy (n¼11) with 27% having a WLE (n¼4). With the PECs and LA infusion group, 80% underwent mastectomy (n¼12) with 20% having a WLE (n¼3). The mean (SD) intraoperative oxycodone consumption was 4.7 (2.2), 6.9 (3.9), and 4.9 (2.9) in PECs, LA infusion, and both groups, respectively; P¼0.3 ( Table 1) .
The pain VRS scores at rest ( Fig. 2A ) and at moving (Fig. 2B ) are shown. There were no significant differences at any single time point. Area under the pain VRS vs time curve (AUC) at rest were [mean (SD)] 45 (27) mm h À1 vs 39 (25) vs 10 (10) in PECs, LA infusion, and both, respectively; P¼0.001, for patients receiving both compared with either PECs or LA infusion alone (Fig. 3A) . Area under the pain VRS vs time (AUC) moving were [mean (SD)] 71 (34) mm h À1 vs 58 (41) vs 23 (20) in PECs, LA infusion, and both, respectively; P¼0.002, for patients receiving both compared with either PECs or LA infusion alone (Fig. 3B) . For each group (PECs, LA infusion, and PECs and LA infusion), there were patients with surgical drains placed. The PECs group had six patients with drains placed (40%). The LA infusion group had nine patients with drains placed (60%), and the PECs and LA infusion groups had nine patients with drains placed (60%). Subgroup analysis of patients that were randomised in this study and had a surgical drain placed did not show any significant difference in AUC, but the study was not powered to detect any difference with these numbers.
The total opioid consumption over 24 h in PECs, LA infusion, and both, respectively (median, 25e75%) was 14 mg (9e26) vs 11 mg (8e24) vs 9 mg (5e11); P¼0.4. 
P a in V R S a t re s t (c m )

Time (h)
PECs only LA infusion Both VRS pain scores on moving are similar over time in the three groups, and there were no significant differences in VRS pain scores at any individual time point. LA infusion, local anaesthetic wound infusion; SD, standard deviation; VRS, verbal rating scale. Patient monitoring and potential adverse-event profile are shown in Table 2 . Adverse events were minimal with no significant difference between the groups with respect to blood pressure, SpO 2 , nausea, vomiting, or pruritus (Fig. 4 ).
Discussion
The current study was performed to compare the analgesic efficacy of single-shot PECs block vs LA infusion vs a combination of both PECs block and LA infusion, in women undergoing non-ambulatory breast surgery. We showed that the area under the pain VRS vs time curve (AUC) was significantly lower in the combined PECs and LA infusion group, both at rest and with movement, in the first 24 postoperative hours. The 24 h mean postoperative opioid consumption was similar between groups, and the incidence of adverse effects was low.
This represents the first reported study to our knowledge comparing single-shot PECs blocks with either LA infusion analgesia or a combination of the techniques. In studies reported previously, the superior analgesia provided by singleshot PECs blocks was limited to the early postoperative period (0e12 h) when compared with TPVB. 13, 14 Given that
PECs blocks are also a single-shot pre-incisional technique, it is plausible to question the quality of late analgesia provided. Trials comparing PECs blocks with placebo may let us assess whether single-shot blocks have a finite duration. Versyck and colleagues 12 recruited patients undergoing lumpectomy or mastectomy, along with either sentinel lymph-node dissection or axillary clearance, and no significant difference in the quality of analgesia was seen after discharge from the PACU. Bashandy and Abbas 11 recruited patients undergoing modified radical mastectomy, and showed a significant reduction in pain visual analogue scale scores continuing to 24 h after operation, although there was no difference in morphine consumption beyond 12 h. Measuring AUC of the VRS pain over 24 h is a way of increasing the sensitivity of subjective pain scores over time. Whilst the AUC value itself is not helpful clinically, the technique evaluates the analgesic effectiveness over the defined period, rather than at a single time, and is therefore an appropriate, relevant, and patient-centred measure of postoperative pain.
All analgesic studies necessarily require subjective assessment of patients' pain. We controlled for its inherent variability by the only tools available: randomisation and 'blinding', which was double blind: neither patients nor outcome evaluators were aware of patient group allocation.
The majority of patients in each of our groups underwent mastectomy with SLNB ± axillary clearance. The heterogeneity of surgical procedures included reflects current pragmatic practice where these techniques (PECs and LA infusion) are used daily, and demonstrating their efficacy in such a realistic patient sample is the strength of the study. In any event, randomisation ensured that similar proportions of the different types of surgery were present in each of our study groups.
Our present data suggest that PECs blocks provide adequate early analgesia, but this effect begins to diminish after 4 h. Alternatively, our patients studied had relatively low pain scores beyond the early postoperative period, making it difficult to detect differences in the quality of early analgesia provided. Taking these studies into account, it is possible to conclude that the effectiveness of single-shot PECs blocks may begin to diminish after the early postoperative period, but remains superior to placebo in patients undergoing more invasive surgery.
LA infusion analgesia provides superior late analgesia when compared with single-shot TPVB, although the quality of early analgesia is inferior. 8 There are no prior reported studies comparing single-shot PECs block with LA infusion analgesia. As single-shot regional techniques give excellent early analgesia and LA infusion provides excellent late analgesia, it seemed reasonable to consider that a combination approach may afford optimum analgesia after breast surgery. Our study shows this to be the case, with significantly lower pain VRS AUC experienced by patients in the combined group, both at rest and with movement. Although there were no significant differences at any single time point, the trend is towards lower early pain scores in the PECs group, which become higher in the later postoperative periods, with the reverse being seen in the LA infusion group. Pain scores in the combined group are consistently low from the early to late postoperative period. In this study, the mean total opioid consumption in the 24 h after operation was similar, at 14 mg (9e26), 11 mg (8e24), and 9 mg (5e11) in the PECs, LA infusion, and PECs and LA infusion Table 2 Monitoring and adverse events profile. All data shown mean (standard deviation) or n (%). DBP, diastolic blood pressure; LA infusion, local anaesthetic wound infusion; SBP, systolic blood pressure. Other adverse events are reported as any incidence over the 24 h observation period. There were no significant differences between the three groups whilst the other studies, ours included, used levobupivacaine 0.25%, 30 ml. The patients in these studies, like ours, received opioid patient-controlled analgesia i.v. in PACU, but the patients in our study received oxycodone orally after PACU discharge whilst on the ward. Oral analgesia postoperatively facilitates early mobilisation and enhanced recovery, in keeping with current trends in clinical practice, although patients are reliant on nursing staff to administer rescue analgesia. Both this and the morphine-to-oxycodone conversion make it difficult to compare postoperative opioid use between the studies accurately. The incidence of adverse effects was low in all groups, and only a small number in each group required an additional anti-emetic after operation for nausea or vomiting. We recognise there are limitations with this study. Although the study was powered to detect the primary outcome, a 25% difference in pain VRS AUC, pilot studies upon which power calculations are based are often underpowered and could yield an imprecise estimate of the difference in the population. Indeed, this could well have yielded an imprecise estimate of the population receiving these blocks, but the justification for undertaking this study was precisely the lack of reported formal evaluation, in a randomised controlled trial (RCT), of the analgesic efficacy of the PECs blocks compared with LA infusion. Using the upper limit of the 95% confidence interval of the variance derived from internal pilot studies has been shown to improve the precision of sample-size estimation, 17 but we did not use this.
Formal dermatomal cold-sensation testing was not undertaken after operation. Doing so in patients who received a PECs block would have undermined patient masking to their group allocation, but omitting this testing means a lack of confirmation of correct block delivery. We assessed 186 patients for eligibility, and randomised 45. The majority of patients were not included for logistical reasons, which may be interpreted as selection bias, although the randomised double-blind design should provide reassurance.
In conclusion, in this single-centre RCT, the combination of both pre-incisional single-shot PECs blocks and postoperative LA infusion provided better postoperative analgesia over 24 h than either technique alone after non-ambulatory breastcancer surgery. Further work is required to compare continuous PECs catheters and continuous paravertebral catheters over 24e48 h, and whether any of these anaesthetic analgesic techniques for breast surgery definitively reduces the risk of chronic persistent breast pain.
